bioAffinity reports FY2022 net loss $8.2M ($1.81/sh), revenue $5K; cash $11.4M, plans pivotal trial 2023

bioAffinity Technologies, Inc.

2024-Q1 EPS reported -$0.18 revenue$1,806,196

FY2022 net loss $8.2M ($1.81/sh) vs $6.3M ($2.36/sh) in 2021; revenue $5K from CyPath Lung LDT.
Q4 2022 net loss $1.7M, revenue $2,500; cash and equivalents $11.4M as of Dec 31, 2022.
Raised net $6.0M from IPO in Sep 2022; additional $7.8M from warrant/option exercises.
CyPath Lung clinical validation: 92% sensitivity, 87% specificity in high-risk patients; AUC 94%.
Pivotal trial for FDA clearance to recruit 1,800 patients starting in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2022 results: revenue approximately $2,500, net income Net loss for the fourth quarter of 2022 was $1.7 million.

Period: the three and 12 months ended December 31, 2022
Revenue: approximately $2,500
Net income: Net loss for the fourth quarter of 2022 was $1.7 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.

View on SEC.gov

Browse all earnings releases →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.